BI KRASmulti, a First-in-class, Orally Bioavailable and Direct Inhibitor of Diverse Oncogenic KRAS Variants Drives Tumor Regression in KRAS G12V-driven Preclinical Models David H. Peng , Antonio Tedeschi , Lorenz Herdeis , Fabio Savarese , Francesca Rocchetti , Popow Johannes , Heinrich J. Huber , Nicola Melillo , Jake Dickinson , Hitesh B. Mistry , Birgit Wilding , Matthias Treu , Julian Fuchs , Joachim Broker , Tobias Wunberg , Fiorella Schischlik , Jesse Lipp , Vandhana Ramamoorthy , Joseph R. Daniele , Scott Kopetz , Michael Kim , Don L. Gibbons , Christopher P. Vellano , Joseph R. Marszalek , Timothy P. Heffernan , Darryl McConnell , Mark Pearson , Norbert Kraut , Dorothea Rudolph MOLECULAR CANCER THERAPEUTICS（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
